Jazz Pharmaceuticals (NASDAQ: JAZZ)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-02 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 3.830 | 3.730 | -0.1000 | ||||
REV | 853.520M | 813.721M | -39.799M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Jazz Pharmaceuticals (NASDAQ: JAZZ) through any online brokerage.
Other companies in Jazz Pharmaceuticals’s space includes: Novo Nordisk (NYSE:NVO), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), Novartis (NYSE:NVS) and Roivant Sciences (NASDAQ:ROIV).
The latest price target for Jazz Pharmaceuticals (NASDAQ: JAZZ) was reported by UBS on Tuesday, June 14, 2022. The analyst firm set a price target for 194.00 expecting JAZZ to rise to within 12 months (a possible 22.34% upside). 13 analyst firms have reported ratings in the last year.
The stock price for Jazz Pharmaceuticals (NASDAQ: JAZZ) is $158.58 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Jazz Pharmaceuticals.
Jazz Pharmaceuticals’s Q2 earnings are confirmed for Tuesday, August 2, 2022.
There is no upcoming split for Jazz Pharmaceuticals.
Jazz Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.